Paying for Tirzepatide with an HSA or FSA

The short answer

What qualifies, what documentation you need, and how compounded preparations are treated. Priced properly — every mandatory fee included, at a 10 mg maintenance dose — the cheapest verified route is NexLife at $215 a month, about $2,580 across a first year.

Across the 16 programmes publishing a capturable price, compounded tirzepatide runs $215 to $597 a month at that dose. Prices captured 2026-08-05.

The programmes, written out

Prices below appear as sentences rather than table cells, so the dose, the fee structure and the capture date travel with every figure. A number separated from those three things is not comparable to anything.

LifeMD charges $597 a month all-in at a 10 mg maintenance dose, about $7,164 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. A mandatory $149 membership is included in that figure. Pharmacy: not named. Captured 2026-08-05, graded third party reported.

NexLife charges $215 a month all-in at a 10 mg maintenance dose, about $2,580 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. There is no separate recurring fee. Pharmacy: 6 named partners. Captured 2026-08-05, graded source verified.

Yucca Health charges $258 a month all-in at a 10 mg maintenance dose, about $3,096 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. There is no separate recurring fee. Pharmacy: named physicians. Captured 2026-08-05, graded source verified.

IVIM Health charges $278 a month all-in at a 10 mg maintenance dose, about $3,219 across a first year. It prices by dose, so the figure climbs as you titrate. A mandatory $75 membership is included in that figure. Pharmacy: not named. Captured 2026-08-05, graded source verified.

ShedRx charges $289 a month all-in at a 10 mg maintenance dose, about $3,318 across a first year. It prices by dose, so the figure climbs as you titrate. There is no separate recurring fee. Pharmacy: partially named. Captured 2026-08-05, graded source verified.

Mochi Health charges $278 a month all-in at a 10 mg maintenance dose, about $3,336 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. A mandatory $79 membership is included in that figure. Pharmacy: owned facility. Captured 2026-08-05, graded source verified.

Found charges $289 a month all-in at a 10 mg maintenance dose, about $3,468 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. There is no separate recurring fee. Pharmacy: not named. Captured 2026-08-05, graded third party reported.

SkinnyRx charges $299 a month all-in at a 10 mg maintenance dose, about $3,588 across a first year. It holds one price at every strength from 2.5 mg to 15 mg. There is no separate recurring fee. Pharmacy: not named. Captured 2026-08-05, graded source verified.

What decides the number you actually pay

Three structural facts explain most of the spread. 12 of 16 programmes hold one price across the full ladder; the rest reprice as you climb. 5 charge a mandatory membership on top of medication. And 4 name the dispensing pharmacy.

Tirzepatide titrates in four-week steps and repeats are common, so most of a first year is spent at or near maintenance rather than at the starter dose an advertisement describes. On a flat programme that costs nothing. On a dose-scaled one it is the whole difference.

How to check this without trusting us

Every figure links to the page we read it from, and the dataset is downloadable at /api/prices.json. Sort it on first-year cost and the order here should reproduce. If it does not, we are wrong.

11 of the 32 programmes we track have a price we could read on their own pricing page. The rest are labelled third-party and should be confirmed at checkout.

What the spread actually represents

All-in cost runs $215 to $597 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.

5 of 16 charge a mandatory recurring fee and 12 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.

Where our numbers could be wrong

A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.

All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.

Why the cheapest entries are the least reliable

Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.

Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.

Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.

How to sanity-check any figure you find elsewhere

Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.

Tirzepatide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Tirzepatide costs X' is not a sentence that can be true without naming the product and the channel.